Metabet Sr (Metformin Hydrochloride)

Metformin reduces hepatic glucose output by inhibiting mitochondrial complex I, limits intestinal glucose absorption, and enhances peripheral insulin sensitivity. These actions collectively lower fasting and post‑prandial blood glucose without stimulating insulin secretion.

The dosage of Metabet Sr is individualized. A qualified prescriber determines the appropriate strength, frequency, and titration schedule based on the patient’s renal function, glycaemic targets, and overall clinical condition.

Safety data for metformin during pregnancy and lactation are limited. It is generally avoided unless the potential maternal benefit outweighs possible fetal risk, and it should be used under close medical supervision in these populations.

To place an order, submit an enquiry on the Metabet Sr product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, metformin (Metabet Sr) does not stimulate insulin release, which reduces the risk of hypoglycaemia. It also promotes modest weight loss and has a favourable cardiovascular profile, making it a preferred first‑line option for many patients with type 2 diabetes.

Metabet Sr should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Metabet Sr is taken orally, usually with meals to minimise gastrointestinal upset. Tablets should be swallowed whole with a full glass of water; they are not intended for crushing, chewing, or sublingual administration.

The most critical safety concerns are lactic acidosis—a rare but potentially fatal metabolic disturbance—and severe hypoglycaemia when metformin is combined with insulin or insulin‑secretagogues. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or unexplained fatigue develop.

Metabet Sr is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in those with conditions that predispose to hypoxia, such as severe heart or respiratory failure.